Skip to content
CancerIndex

Loading the knowledge graph…

Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers — knowledge graph · CancerIndex